

Korea's GCCL partners with OPIS to advance global clinical trial capabilities

16 January 2026 | News

GCCL aims to expand strategic partnerships with global CROs and research organisations



GCCL, a leading South Korea-based provider of clinical trial sample analysis, and US-based OPIS, a global full-service contract research organization (CRO), have signed a Memorandum of Understanding (MoU) to expand their collaboration and strengthen their position in the global clinical trial market.

With the rising proportion of multinational clinical trials, sponsors face varying regulatory requirements, clinical environments, and data demands across regions, driving growing demand for tailored CRO services. GCCL and OPIS will address these needs by combining their expertise to deliver integrated solutions that optimise clinical trial planning, sample analysis, and data management, offering comprehensive and customized services for biopharmaceutical companies in Europe and Asia.

At the signing ceremony, representatives from both companies discussed establishing a collaborative framework across multiple areas, including joint global clinical trial services, conducting joint projects, development of new business opportunities, and additional initiatives.

Through this collaboration, GCCL aims to expand strategic partnerships with global CROs and research organizations, strengthen its capability to deliver fully integrated clinical trial solutions across Asia, Europe, and the Americas, and extend tailored services to a broader range of biopharmaceutical companies.